Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Journal of the Neurological Sciences|April 28, 2009
Connecting white matter injury and thalamic atrophy in clinically isolated syndromesRoland G Henry, Mason Shieh, Bagrat Amirbekian, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 30, 2017
Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiationKaty Wright, Mandy D Winkler, Braeden D Newton, et al.
Frontiers in Neurology|July 14, 2023
Do magnetic resonance imaging features differ between persons with multiple sclerosis of various races and ethnicities?Nabeela Nathoo, Burcu Zeydan, Nur Neyal, et al.
Multiple Sclerosis and Related Disorders|January 7, 2023
Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorderAlexander D Smith, Tatum M Moog, Katy W Burgess, et al.
Multiple Sclerosis and Related Disorders|October 22, 2023
Investigating the link between regional oxygen metabolism and cognitive speed in multiple sclerosis: Implications for fatigueMark D Zuppichini, Dinesh K Sivakolundu, Kathryn L West, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|June 15, 2023
MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody diseaseEdgar Carnero Contentti, Darin T Okuda, Juan I Rojas, et al.
Annals of Neurology|June 6, 2020
Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical EventChristine Lebrun-Frenay, Orhun Kantarci, Aksel Siva, et al.
Multiple Sclerosis and Related Disorders|October 7, 2023
Treatment transitions in neuromyelitis optica spectrum disorder increase risk for disease advancementDarin T Okuda, Tatum M Moog, Morgan McCreary, et al.
Multiple Sclerosis and Related Disorders|June 6, 2022
Hiding in plain sight: The magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of careDarin T Okuda, Katy W Burgess, Karin Cook, et al.
Neurology and Therapy|December 19, 2022
Sphingosine-1 Phosphate Receptor Modulators Increase In Vitro Melanoma Cell Line Proliferation at Therapeutic Doses Used in Patients with Multiple SclerosisCaroline Ruetsch-Chelli, Darin T Okuda, Fanny Rocher, et al.
Pageof 11